2. Blencowe H, Cousens S, Oestergaard MZ, Chou D, Moller AB, Narwal R, et al. National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications. Lancet 2012;379:2162-72.
3. Liu L, Johnson HL, Cousens S, Perin J, Scott S, Lawn JE, et al. Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000. Lancet 2012;379:2151-61.
5. Esplin MS, Manuck TA, Varner MW, Christensen B, Biggio J, Bukowski R, et al. Cluster analysis of spontaneous preterm birth phenotypes identifies potential associations among preterm birth mechanisms. Am J Obstet Gynecol 2015;213:429.e1-9.
6. Rubens CE, Sadovsky Y, Muglia L, Gravett MG, Lackritz E, Gravett C. Prevention of preterm birth: Harnessing science to address the global epidemic. Sci Transl Med 2014 6:262sr5.
7. Serra V, Perales A, Meseguer J, Parrilla JJ, Lara C, Bellver J, et al. Increased doses of vaginal progesterone for the prevention of preterm birth in twin pregnancies: a randomised controlled double-blind multicentre trial. BJOG 2013;120:50-7.
8. Hermans FJ, Karolinski A, Othenin-Girard V, Bertolino MV, Schuit E, Salgado P, et al. Population differences and the effect of vaginal progesterone on preterm birth in women with threatened preterm labor (.). J Matern Fetal Neonatal Med 2016;29:3223-8.
9. Tita AT, Rouse DJ. Progesterone for preterm birth prevention: an evolving intervention. Am J Obstet Gynecol 2009;200:219-24.
10. Shaamash AH, Ali MK, Attyia KM. Intramuscular 17α-hydroxyprogesterone caproate to decrease preterm delivery in women with placenta praevia: a randomised controlled trial. J Obstet Gynaecol 2020;40:633-8.
11. Saghafi N, Khadem N, Mohajeri T, Shakeri MT. Efficacy of 17α-hydroxyprogesterone caproate in prevention of preterm delivery. J Obstet Gynaecol Res 2011;37:1342-5.
12. Meis PJ, Klebanoff M, Thom E, Dombrowski MP, Sibai B, Moawad AH, et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med 2003;348:2379-85.
13. Ibrahim M, Mohamed Ramy AR, Younis MAF. Progesterone supplementation for prevention of preterm labor: A randomized controlled trial. Middle East Fertil Soc J 2010;15:39-41.
14. Grobman WA, Thom EA, Spong CY, Iams JD, Saade GR, Mercer BM, et al. 17 alpha-hydroxyprogesterone caproate to prevent prematurity in nulliparas with cervical length less than 30 mm. Am J Obstet Gynecol 2012;207:390.e1-8.
15. American College of Obstetricians and Gynecologists. ACOG committee opinion. Use of progesterone to reduce preterm birth. Obstet Gynecol 2003;102(5 Pt 1):1115-6.
16. Blackwell SC, Gyamfi-Bannerman C, Biggio JR Jr, Chauhan SP, Hughes BL, Louis JM, et al. 17-OHPC to prevent recurrent preterm birth in singleton gestations (PROLONG study): a multicenter, international, randomized double-blind trial. Am J Perinatol 2020;37:127-36.
17. Jafarpour H, Mousavi SJ, Mirghorbani M, Razavi AR, Atarod Z. Effect of 17 α-hydroxyprogesterone caproate on the prevention of preterm labor: a randomized controlled trial study. J Midwifery Reproductive Health 2020;8:2317-23.
18. Fernandez-Macias R, Martinez-Portilla RJ, Cerrillos L, Figueras F, Palacio M. A systematic review and meta-analysis of randomized controlled trials comparing 17-alpha-hydroxyprogesterone caproate versus placebo for the prevention of recurrent preterm birth. Int J Gynaecol Obstet 2019;147:156-64.
20. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.2 [Internet] London (UK): Cochrane; c2021 [cited 2021 May 13]. Available from:
www.training.cochrane.org/handbook
.
23. Berghella V, Figueroa D, Szychowski JM, Owen J, Hankins GD, Iams JD, et al. 17-alpha-hydroxyprogesterone caproate for the prevention of preterm birth in women with prior preterm birth and a short cervical length. Am J Obstet Gynecol 2010;202:351.e1-6.
24. Pirjani R, Heidari R, Rahimi-Foroushani A, Bayesh S, Esmailzadeh A. 17-alpha-hydroxyprogesterone caproate versus vaginal progesterone suppository for the prevention of preterm birth in women with a sonographically short cervix: a randomized controlled trial. J Obstet Gynaecol Res 2017;43:57-64.
25. Choi SJ, Kwak DW, Kil K, Kim SC, Kwon JY, Kim YH, et al. Vaginal compared with intramuscular progestogen for preventing preterm birth in high-risk pregnant women (VICTORIA study): a multicentre, open-label randomised trial and meta-analysis. BJOG 2020;127:1646-54.
28. Ning A, Vladutiu CJ, Dotters-Katz SK, Goodnight WH, Manuck TA. Gestational age at initiation of 17-alpha hydroxyprogesterone caproate and recurrent preterm birth. Am J Obstet Gynecol 2017;217:371.e1-371.e7.
30. Sibai B, Saade GR, Das AF, Gudeman J. Safety review of hydroxyprogesterone caproate in women with a history of spontaneous preterm birth. J Perinatol 2021;41:718-25.